	US 12,305,173 B2
	Immunostimulatory compositions
Thomas Ilg, Monheim (DE)
Assigned to Elanco Animal Health GmbH, Monheim am Rhein (DE)
Filed by Elanco Animal Health GmbH, Monheim am Rhein (DE)
Filed on Aug. 8, 2022, as Appl. No. 17/883,031.
Application 17/883,031 is a continuation of application No. 16/772,046, granted, now 11,542,507, previously published as PCT/EP2018/083956, filed on Dec. 7, 2018.
Claims priority of application No. 17207740 (EP), filed on Dec. 15, 2017; application No. 17207746 (EP), filed on Dec. 15, 2017; and application No. 17207750 (EP), filed on Dec. 15, 2017.
Prior Publication US 2023/0174990 A1, Jun. 8, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 31/7088 (2006.01); A61K 39/39 (2006.01); A61P 37/02 (2006.01); A61P 37/04 (2006.01); C12N 15/117 (2010.01)

CPC C12N 15/117 (2013.01) [A61K 39/39 (2013.01); A61P 37/04 (2018.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/60 (2013.01); C12N 2310/17 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/31 (2013.01)]

20 Claims

1. An immunostimulatory oligonucleotide comprising at least one CpG motif and a guanine nucleotide enriched sequence beginning at or within four nucleotides of the 5′ terminus of the immunostimulatory oligonucleotide, wherein the guanine nucleotide enriched sequence comprises TTAGGG, TTAGGGTTAGGG (SEQ ID NO:261), TTTTGGGG, GGGGTTTT, GGGGTTTTGGGG (SEQ ID NO:262), TTAGGG, TTAGGGTTAGGGTTTT (SEQ ID NO: 263), TGTGGGTGTGTGTGGG (SEQ ID NO:269), GGAGG, TGGAGGC, TGGAGGCTGGAGGC (SEQ ID NO:264), or TGGGGT.